Medivir Posts 7-day Data for Osteo Candidate

Medivir AB has posted results from its Phase I study of cathepsin K inhibitor MIV-711 for the treatment of osteoarthritis and other bone related disorders. The seven-day trial data included the following findings:

• Serum levels of the bone resorption marker CTX-I were suppressed in a dose-dependent manner with up to 55% at 24 hours post last dose on Day 7
• Urinary excretion of the cartilage degradation marker CTX-II was reduced in a dose-dependent manner with up to 72% post last dose on Day 7
• Similar effects were seen in post-menopausal women dosed once daily for 28 days at 100 mg
• MIV-711 was generally safe and well tolerated at all doses and durations tested

The results, the company contends, demonstrate MIV-711’s safety and tolerability at doses where it potently decreased cartilage degradation and bone resorption as suggested by the biomarker data.

MIV-711 is a potent and selective investigational cathepsin K inhibitor for the treatment of skeletal disorders such as osteoarthritis and osteoporosis. Cathepsin K is an enzyme important for bone and cartilage break-down and inhibition of cathepsin K is expected to have a positive effect on these diseases. Preclinical data with MIV-711 have demonstrated significant reductions of biomarkers for bone and cartilage degradation and encouraging protective effects in experimental models of osteoarthritis.